LOGIN  |  REGISTER
Terns Pharmaceuticals

West's Ready Pack™ containment solution with Corning® Valor® RTU Vials utilizing Stevanato Group's EZ-fill® technology recognized for Best Technologies Award at INTERPHEX

May 02, 2023 | Last Trade: US$314.49 23.63 -6.99

EXTON, Pa., May 2, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, is pleased to announce that its West Ready Pack™ containment solution with Corning® Valor® RTU Vials utilizing Stevanato Group's EZ-fill® technology recently won the Best Technologies Award at INTERPHEX. The Best Technologies Award recognizes cutting-edge technologies, either new technologies or a novel implementation of existing technologies, that have the potential to change the way pharmaceutical and biotechnology companies operate.

Stacey Vaughan, West Senior Director, Strategic Marketing (center) accepting award with INTERPHEX leadership

"West is honored to receive the Best Technologies Award at INTERPHEX, recognizing West's Ready Pack with Corning® Valor® RTU Vials utilizing Stevanato Group's EZ-fill® technology," said Chris Ryan, Senior Vice President, Containment and Glass Systems. "This product is the first of many containment systems products to come from West; through this specific offering we meet the needs of drug developers to quickly source a complete vial containment product that can easily scale up from early drug development to commercialization." 

This version of West's Ready Pack™ containment solution combines West's highest quality NovaPure® stoppers, Flip-Off® CCS (Clean, Certified, Sterilized) seals and Corning's best-in-class Valor® RTU Vials utilizing Stevanato Group's EZ-fill® technology into a complete containment solution to help bring parenteral drugs and diagnostics to market.  West Ready Pack™ containment solution components are particularly well-suited for R&D purposes or small filling operations and are designed to support a smooth transition from early-stage biopharmaceutical pilot assessments to larger commercial-scale manufacturing.  

For more information about West, please visit our website: http://www.westpharma.com

For more information about the INTERPHEX Conference, please visit: INTERPHEX

About West 

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 47 billion components and devices each year. 

2023 marks West's 100-year milestone of innovation and the critical role it continues to play in healthcare and the patient experience. Headquartered in Exton, Pennsylvania, West in its fiscal year 2022 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

© 2023 West Pharmaceutical Services, Inc. 

West and the diamond logo, Ready Pack, Flip-Off, and NovaPure are trademarks or registered trademarks of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.   

Corning® and Valor® are registered trademarks of Corning Incorporated.   

EZ-fill is a registered trademark of Stevanato Group.  

West Pharmaceutical Services, Inc. is the exclusive distributor of Corning® Valor® Glass vials.  

 

Astria Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB